Literature DB >> 12057830

Utility scores of symptom profiles in major depression.

Ayal Schaffer1, Anthony J Levitt, Susan K Hershkop, Paul Oh, Cathy MacDonald, Krista Lanctot.   

Abstract

Utility is a measure of undesirability for a specific health state. This study determines the utility scores for the individual symptoms of depression, and examines the impact that personal experience with depression has on these scores. Seventy-five subjects (19 with current depression, 21 with past depression, and 35 healthy controls) assigned utility scores to each of 10 individual symptoms of depression, and three depression severity profiles. Utility scores were measured using the standard gamble technique. Mean utility scores were used to list the symptoms of depression from most to least undesirable. The three diagnostic groups were compared with respect to the magnitude of undesirability of the depressive symptoms. The results of this study found that individuals assigned different utility scores to different symptoms of depression. The psychological symptoms of depression such as suicidal ideation, guilt and depressed mood were ranked as more undesirable than the somatic symptoms of depression. Each diagnostic group ranked the symptoms of depression in a similar manner. Patients with a current depression were willing to accept a greater risk of death to avoid suffering from lifelong depressive symptoms as compared to patients with a past depression or healthy controls.

Entities:  

Mesh:

Year:  2002        PMID: 12057830     DOI: 10.1016/s0165-1781(02)00097-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Utility scores for vesicoureteral reflux and anti-reflux surgery.

Authors:  Caleb P Nelson; Jonathan C Routh; Tanya Logvinenko; Ilina Rosoklija; Paul J Kokorowski; Lisa A Prosser; Mark A Schuster
Journal:  J Pediatr Urol       Date:  2015-04-30       Impact factor: 1.830

2.  Losing sight of the wood for the trees: some issues in describing and valuing health, and another possible approach.

Authors:  Paul Dolan; Henry Lee; Tessa Peasgood
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

3.  Predictors of health-related quality-of-life utilities among persons with posttraumatic stress disorder.

Authors:  Jason N Doctor; Lori A Zoellner; Norah C Feeny
Journal:  Psychiatr Serv       Date:  2011-03       Impact factor: 3.084

Review 4.  Does evidence-based medicine apply to psychiatry?

Authors:  Mona Gupta
Journal:  Theor Med Bioeth       Date:  2007-05-15

5.  Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2019-02-19

Review 6.  A decision analysis of long-term lithium treatment and the risk of renal failure.

Authors:  U Werneke; M Ott; E Salander Renberg; D Taylor; B Stegmayr
Journal:  Acta Psychiatr Scand       Date:  2012-03-09       Impact factor: 6.392

7.  Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review.

Authors:  Sorrel E Wolowacz; Peter M Classi; Julie Birt; Evelina A Zimovetz
Journal:  Cost Eff Resour Alloc       Date:  2012-02-01

Review 8.  Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-11-13

9.  When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study.

Authors:  Roy H Perlis; Amanda Patrick; Jordan W Smoller; Philip S Wang
Journal:  Neuropsychopharmacology       Date:  2009-06-03       Impact factor: 7.853

10.  Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder.

Authors:  Christophe Sapin; Bruno Fantino; Marie-Laure Nowicki; Paul Kind
Journal:  Health Qual Life Outcomes       Date:  2004-05-05       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.